Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2024-04-26 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司股东大会议事规则
Governance Information Classification · 95% confidence The document is titled "股东大会议事规则" which translates to "Rules of Procedure for the Shareholders' General Meeting". It details the procedures, rights, and responsibilities related to the convening and conduct of shareholders' meetings, including annual and extraordinary general meetings. It references relevant laws and regulations governing shareholder meetings and outlines the rules for proposals, notifications, voting, and meeting conduct. There is no financial data, earnings information, or report content. Instead, it is a governance document outlining internal rules and procedures for shareholder meetings. Therefore, it fits best under Governance Information (CGR). The document length (7275 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive governance rules document.
2024-04-26 Chinese
圣湘生物科技股份有限公司第二届董事会2024年第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's 2024 third board meeting. It includes multiple agenda items such as approval of the 2023 annual board work report, 2023 annual report and summary, 2023 ESG report, 2024 Q1 report, remuneration plans, internal control evaluation, appointment of auditors, capital changes, and plans for the 2023 annual shareholders meeting. The document is not the reports themselves but rather the board's approval and decisions regarding these reports and other governance matters. It also references that the full reports are published separately on the stock exchange website. The document is a formal board meeting resolution announcement, which fits best under Board/Management Information (MANG) as it details board meeting decisions and management-related approvals. It is not a full annual report (10-K), nor a simple announcement of report publication (RPA), nor a proxy or voting result announcement (DVA). The length and content confirm it is a substantive board meeting resolution document.
2024-04-26 Chinese
中审众环会计师事务所（特殊普通合伙）关于圣湘生物科技股份有限公司募集资金年度存放与实际使用情况的鉴证报告
Regulatory Filings
2024-04-26 Chinese
中审众环会计师事务所（特殊普通合伙）关于圣湘生物科技股份有限公司内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report." It is issued by a certified public accounting firm and addresses the effectiveness of the company's internal control over financial reporting as of December 31, 2023. The content includes the auditor's responsibilities, the company's responsibilities, and an audit opinion on internal control effectiveness. There is no indication that this is a full annual report or interim financial report; rather, it is a standalone audit report focused on internal control. The document length is 4251 characters, which is relatively short but contains substantive audit content, not just an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2023
2024-04-26 Chinese
圣湘生物科技股份有限公司2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2023 年年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed financial data for the year 2023, including revenue, net profit, quarterly financial data, shareholder information, business overview, industry analysis, and risk factors. The document is comprehensive and exceeds 5,000 characters, indicating it is not a mere announcement or summary notice but a substantive report. It includes management discussion and analysis, financial metrics, and operational details typical of an Annual Report. There is also mention of an audit report with an unqualified opinion, which is commonly included or referenced in annual reports. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-26 Chinese
圣湘生物科技股份有限公司董事会议事规则
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors'. It details the internal rules, procedures, and governance practices for the company's board meetings, including meeting notices, quorum, voting, and record-keeping. There is no financial data, audit information, or report publication mentioned. The content is focused on governance structure and board operations. Therefore, this document fits the category of Governance Information (CGR). The document length is about 5034 characters, which is sufficient for a detailed governance document, not a brief announcement or certification.
2024-04-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.